Oncoinvent ASA

Clinical dosimetry results from Phase 1 studies of Radspherin ® in ovarian and colorectal cancer demonstrate absorbed doses to normal organs well below values associated with toxicity risks The results are consistent with the favorable safety profile observed to date and support the further development of Radspherin ® for treatment of peritoneal metastases OSLO, Norway, 11 August 2026 /PRNewswire/ -- Oncoinvent, a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces the publication of clinical dosimetry data for Radspherin® in the Journal of Nuclear Medicine, one of the leading peer-reviewed journals in the field. The publication, titled ' Normal Tissue Dosimetry of Intraperitoneal Radium-224-Microparticle Therapy: Data from First-in-Human Studies in Patients with Peritoneal Metastases ', reports results from nine patients enrolled in the dosimetry cohorts of the Phase 1 Radspherin® studies in ovarian and colorectal cancer. Positive final data from these studies, previously reported by Oncoinvent, demonstrated a favorable safety profile and encouraging efficacy signals. "In early-phase clinical studies, dosimetry is essential to understand how radiation exposure relates to potential toxicity and identify potential dose-limiting tissues," said Caroline Stokke, senior author of the publication, Head of Nuclear Medicine Physics at Oslo University Hospital and Chair of the European Association of Nuclear Medicine Dosimetry Committee. "This work also reflects the methodological complexity of dosimetry for alpha therapies, where imaging cannot always be directly applied. To address these challenges, we were able to use a combination approach, also including blood sampling and biokinetic modeling, to estimate normal tissue radiation exposure and provide a basis for evaluating safety." The dosimetry study, conducted at The Norwegian Radium Hospital, part of Oslo University Hospital, evaluated how radiation from Radspherin® is distributed to normal tissues following treatment. Results showed that absorbed radiation doses to normal organs were below levels commonly associated with risks for complications, including for organs typically regarded as activity-limiting such as the kidneys and red bone marrow. "We are pleased to report the results from the outstanding work performed together with Oslo University Hospital published in the prestigious Journal of Nuclear Medicine," said Kari Myren, Chief Medical Officer at Oncoinvent. "Unintended radiation exposure to normal organs, especially for the kidneys and red bone marrow, frequently represents a limitation for obtaining therapeutic doses of radiopharmaceuticals. Our results indicate very low radiation exposure to healthy organs after treatment, which is consistent with the favorable safety profile observed in our clinical trials and supports the further development of Radspherin® to provide hope for patients for whom very limited treatment options exist." For further information, please contact: Oystein Soug, Chief Executive Officer Email: [email protected] Optimum Strategic Communications Zoe Bolt, Elena Bates, Katherine Bliss +44 (0) 203 882 9621 [email protected] This information was brought to you by Cision 21% more press release views with Request a Demo

Appointment of experienced executive forms part of the Company’s strategy to build momentum across its proprietary platform and therapeutic programs targeting retinal diseases Company is preparing a Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease Dr Catherine Beech appointed as Director CAMBRIDGE, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the appointment of Olav Hellebø as Chief Executive Officer. Olav will lead the company as it strengthens its executive team and advances toward key clinical and corporate milestones, including initiating a Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease. Olav brings extensive business and scientific leadership experience across the global pharmaceutical and biotechnology sectors, with a distinguished track record in ophthalmology, immunology and oncology. As Chief Executive Officer of ReNeuron Group plc, he in-licensed a Retinitis Pigmentosa programme from the Schepens Eye Research Institute, an affiliate of Harvard Medical School, and completed equity financings totalling $125 million. Olav has held senior commercial and development roles across the United States and Europe. Notably, he served as Executive Vice President at Schering-Plough (now Merck), leading the US Biotech and Oncology business unit, Chief Operating Officer of Novartis UK and a member of the Novartis Global Pharmaceutical Executive Committee, and President of Immunology at UCB where he built and led the Immunology Division following the company’s acquisition of Celltech plc. Olav has been a member of the board of several biotech companies, and currently serves as Director at Oncoinvent and Cytovation, and as Chair at Blue Cell Therapeutics and ION Therapeutics. He graduated Summa Cum Laude in International Business Studies from Hofstra University and holds an MBA from IESE Business School. “We are delighted to welcome Olav as CEO of Exonate," said Dr Rafiq Hasan, Chair of the Board of Directors at Exonate . "Olav combines deep scientific understanding with extensive operational and commercial leadership experience, gained across both large pharmaceutical companies and emerging biotechnology businesses. His expertise in ophthalmology, together with his proven ability to build and lead successful organisations, makes him ideally suited to guide Exonate as we continue to advance our pipeline and create value for patients. I would also like to thank Catherine Beech, one of Exonate’s co-founders, for her time as CEO, and look forward to continuing to work alongside her on the Board of Directors." Olav Hellebø, Chief Executive Officer at Exonate, commented: “Exonate is targeting the VEGF pathway, one of the most validated pathways in retinal disease through a differentiated, topical mechanism delivered as an eye drop, rather than the intravitreal injections used today. We are now ready for a Phase IIb study with a design endorsed by regulators and a clear path to registration, in which a positive result would be confirmed by a closely mirrored Phase III. For the many patients who go untreated rather than accept injections, this is a compelling proposition.” Contacts Katie Odgaard katie.odgaard@zymecommunications.com

Strong recruitment momentum demonstrated in 2026 Year-to-date recruitment has already surpassed total enrollment for 2025 OSLO, Norway, June 18, 2026 /PRNewswire/ -- Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that its ongoing Phase 2 trial of Radspherin® in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the highest recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. "Reaching the halfway point for recruitment in our Phase 2 trial is an important milestone for Oncoinvent and reflects the strong commitment of investigators and study sites," said Oystein Soug, CEO of Oncoinvent. "We are pleased to see the steps taken to accelerate recruitment translating into the strong enrollment momentum seen in 2026. Building on the encouraging safety profile and preliminary efficacy signals observed in earlier studies, we look forward to further evaluating Radspherin's potential to improve outcomes for patients with peritoneal metastases from ovarian cancer, who have limited treatment options following surgery." The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin® in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin® following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin® is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine. For further information, please contact: Oystein Soug, Chief Executive Officer Email: [email protected] Optimum Strategic Communications Zoe Bolt, Elena Bates, Katherine Bliss +44 (0) 203 882 9621 [email protected] This information was brought to you by Cision SOURCE Oncoinvent ASA 21% more press release views with Request a Demo